Xoted Biotechnology Labs

XBiotech is a clinical-stage biopharmaceutical company focused on discovering and developing 'True Human' monoclonal antibodies for the treatment of a wide range of diseases. The company's proprietary technology platform identifies naturally occurring antibodies from individuals who have a resistance to specific diseases, allowing for the development of therapies that mimic the human immune response. Their lead programs target inflammatory conditions and oncology, with a significant focus on neutralizing Interleukin-1 alpha (IL-1a) to treat chronic inflammation and cancer-related cachexia. XBiotech gained significant industry attention following the multi-billion dollar sale of its lead candidate, bermekimab, to Janssen (Johnson & Johnson) in 2019.